The text is from Innovagen.
Sodium hyaluronate (hyaluronic acid—HA) products have been used successfully for years to treat joint disease in several species including man. HA is a normal component of joint fluid and cartilage and serves many functions, one of which is to "lubricate" the soft tissue structures of the joint and decrease inflammation. Until recently, HA products were given only as intra-articular injections, directly into the joint space. There is now an HA preparation that can be given intramuscularly (I.M.) and has shown beneficial results. That product is called Hyaluron.
Although the mechanism of action of HA is not entirely understood, it is recognized that sodium hyaluronate decreases synovial fluid inflammatory mediators (destructive enzymes) which may have a degradative effect upon articular cartilage. In addition to the anti-inflammatory actions, HA acts as a lubricating substance within the joint and provides a "protective barrier" over the synovial membrane.
Hyluron is the joint disease therapy that helps stop acute damage before it becomes chronic. Hyluron is pure hyaluronic acid, the same polysaccharide present in normal joint fluid to protect and lubricate joint cartilage and soft tissues. Hyluron is produced in such purity that it can be given intramuscularly for immediate bioavailability.
A Colorado State University study demonstrated a systemic administration of sodium hyaluronate significantly decreased the synovial fluid concentrations of prostaglandins, glycosaminoglycan (GAG), and total protein that are associated with inflammatory joint disease in the horse. The systemic administration of sodium hyaluronate also decreased the severity of cellular infiltration and vascularity in the synovial membrane (i.e., decreased inflammation at the synovial membrane level). This study demonstrates the systemic administration of sodium hyaluronate decreases inflammation, products associated with inflammation, and the degree of lameness in horses with arthritis (joint inflammation).
Sodium hyaluronate (hyaluronic acid—HA) products have been used successfully for years to treat joint disease in several species including man. HA is a normal component of joint fluid and cartilage and serves many functions, one of which is to "lubricate" the soft tissue structures of the joint and decrease inflammation. Until recently, HA products were given only as intra-articular injections, directly into the joint space. There is now an HA preparation that can be given intramuscularly (I.M.) and has shown beneficial results. That product is called Hyaluron.
Although the mechanism of action of HA is not entirely understood, it is recognized that sodium hyaluronate decreases synovial fluid inflammatory mediators (destructive enzymes) which may have a degradative effect upon articular cartilage. In addition to the anti-inflammatory actions, HA acts as a lubricating substance within the joint and provides a "protective barrier" over the synovial membrane.
Hyluron is the joint disease therapy that helps stop acute damage before it becomes chronic. Hyluron is pure hyaluronic acid, the same polysaccharide present in normal joint fluid to protect and lubricate joint cartilage and soft tissues. Hyluron is produced in such purity that it can be given intramuscularly for immediate bioavailability.
A Colorado State University study demonstrated a systemic administration of sodium hyaluronate significantly decreased the synovial fluid concentrations of prostaglandins, glycosaminoglycan (GAG), and total protein that are associated with inflammatory joint disease in the horse. The systemic administration of sodium hyaluronate also decreased the severity of cellular infiltration and vascularity in the synovial membrane (i.e., decreased inflammation at the synovial membrane level). This study demonstrates the systemic administration of sodium hyaluronate decreases inflammation, products associated with inflammation, and the degree of lameness in horses with arthritis (joint inflammation).

Comment